Nectin cell adhesion molecule 4 (Nectin-4) overexpression in different tumors correlates with cancer progression and poor prognosis in many human malignancies. The first Nectin-4-targeting antibody, enfortumab vedotin (EV), has limited efficacy and frequent adverse effects in several solid tumors. Researchers at Mabwell (Shanghai) Bioscience Co. Ltd. and colleagues have now reported on the generation and characterization of 9MW-2821, an antibody-drug conjugate consisting of an antibody targeting Nectin-4 conjugated to monomethyl auristatin E (MMAE).
Bioray Pharmaceutical Co. Ltd.’s IND application for BRY-812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration (NMPA).
Antengene Corp. Ltd.'s Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has been granted two orphan drug designations consecutively by the FDA for the treatment of gastric cancer and pancreatic cancer.
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
The development of EGFR-targeted tyrosine kinase inhibitors (TKIs) over the past 20 years has modestly improved progression-free survival for patients with metastatic NSCLC. But many patients with EGFR mutations fail to respond to TKI treatments, and immune checkpoint inhibitors elicit a response in less than 10% of NSCLC patients.
Recurium IP Holdings LLC has patented antibody-drug conjugates (ADCs) comprising antibodies targeting inactive tyrosine-protein kinase transmembrane receptor ROR1 covalently bound to exatecan through a linker reported to be useful for the treatment of cancer.
Legochem Biosciences Inc. has entered into a license agreement with Elthera AG to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.